Engineered immune cells target Tough-to-Treat leukemia in early trial
NCT ID NCT02159495
Summary
This early-stage study is testing a new type of CAR T-cell therapy for adults with acute myeloid leukemia (AML) or a related blood cancer that has come back or not responded to other treatments. Doctors take a patient's or a donor's immune cells, genetically modify them to better target cancer cells, and infuse them back into the patient after a short course of chemotherapy. The main goals are to find a safe dose and see if the treatment can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.